https://cgs21680agonist.com/?p=4744preview=true
Kidney transplant recipients, in spite of the vaccination schedule (initial, third, and fourth doses), displayed subpar immune responses. The situation of patients with a persistently negative humoral response, who do not seroconvert after booster doses, is especially cause for worry. With respect to this, monoclonal antibodies designed to target the SARS-CoV-2 virus have been approved for use with high-risk patients, although they could lose their efficacy as the virus's genome mutates. Lessons from the SENCOVAC study are highlighte
Curtir
Comentario
Compartilhar
